Ian Hann

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

Life Sciences, Hematology, Oncology +12

A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial

Rob Pieters, Martin Schrappe, Paola De Lorenzo et al. · The Lancet · 2007 · 653 citations

Medicine, Hematology, Pediatrics +14

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

Alan K. Burnett, Anthony H. Goldstone, Richard MF Stevens et al. · The Lancet · 1998 · 565 citations

Medicine, Hematology, Oncology +15

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

H. G. Prentice, Ian Hann, Raoul Herbrecht et al. · British Journal of Haematology · 1997 · 438 citations

Medicine, Pharmacology, Pharmacotherapy +17

A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

Keith Wheatley, Alan K. Burnett, Anthony H. Goldstone et al. · British Journal of Haematology · 1999 · 435 citations

Medicine, Hematology, Oncology +14